Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

Next Previous
Trial Profile

Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy

Status: Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 13 Nov 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Thrombomodulin alfa (Primary)
  • Indications Blood coagulation disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Scarlet2
  • Sponsors Asahi Kasei Pharma America Corp

Most Recent Events

  • 19 Jun 2019 This trial has been discontinued in Spain, according to European Clinical Trials Database.
  • 11 Jun 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 07 Jun 2019 This trial has been discontinued in France, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top